54 results about "Uveal tract" patented technology

Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.

The invention discloses an application of NRP1 in prevention and treatment of acute anterior uveitis. Researches find that expression deletion of the NRP1 promotes polarization of macrophages to M1, expression of the NRP1 in an iris-ciliary body compound of an acute anterior uveitis model mouse is reduced, an inhibitor of the NRP1 promotes the inflammation phenotype of the acute anterior uveitis model mouse, the NRP1 protein inhibits the phenotype of the acute anterior uveitis model mouse, and the NRP1 protein inhibits the inflammation phenotype of the acute anterior uveitis model mouse. The expression deletion of the NRP1 in the macrophages aggravates the inflammation phenotype of an acute anterior uveitis model mouse, so that the NRP1 can be used for preventing and / or treating the acute anterior uveitis and has a very good application prospect.

Some embodiments of the invention advantageously leverage the expansion, dilation or by-pass of the Schlemm's canal using adjustable reversible self-expanding eye stents (SES) or eye tension rings (ETRs) of desired sizes to control and improve aqueous flow throughout the range of the uveolymphatic canal. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the Schlemm's canal wall and is at least partially within the canal and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the wall and / or elsewhere in the canal. The partial or complete expansion of the canal can be pre-configured based on pre-operative metrology of the Schlemm's canal to a customized and adjustable fit across the various zones within the uveolymphatic canal and based on the patient specific and evolving needs. Additionally, the SES can utilize entry / exit features for by-pass of fluid, varying control of dilation across its shape that may also allow anchoring, repositioning, and retrieval.

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention relates to a method for simultaneously detecting a plurality of pathogens from biologically-derived samples, and a kit for carrying out the method. Specifically, the present invention relates to a method for simultaneously detecting a plurality of pathogens that cause infectious uveitis, one of eye infections from samples such as anterior chamber fluid or vitreous by polymerase chain reaction (PCR), and a kit for carrying out the method.

The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.

Disclosed is a method for treating an ocular inflammatory disease (OID), e. g., uveitis conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway. This application also provides a method for treating a subject suffering from an autoimmune disease-associated ocular inflammation comprising periodic ocular administration to the subject a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt, and an ocular pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating an autoimmune disease-associated ocular inflammation.

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

The present invention relates to a method of predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The invention also relates to an IL-6 antagonist for use in the treatment of uveitis or uveitis macular edema.

The application belongs to the technical field of biological medicine and nanomaterials, and particularly relates to a kind of bionic nano drug delivery system, preparation method and application in eye immunotherapy.The application is with mesoporous SiO2 Nanomicrosphere as core, after protonation treatment, load sCD83, and coat mature DC cell membrane, form DCM@MSN / sCD83 nano drug delivery system.The preparation method of the application has high biocompatibility and simple operation, and the system can actively target mature DC after vitreous injection, release sCD83 and induce mature DC to transform into resistant DC, secrete IL-10 and TGF-β and other anti-inflammatory factors, inhibit STING path activation, reduce retinal inflammatory damage;At the same time, it can penetrate blood-ocular barrier into peripheral circulation, induce mature DC differentiation in neck lymph nodes and spleen and other immune organs, realize local and systemic synergistic immunoregulation, and can be used for preparing medicaments for treating experimental autoimmune uveitis.

The present application provides an acesulfame implant which is stable, safe and can achieve at least 6 months of sustained release, can effectively treat various eye diseases including but not limited to glaucoma, cataract, retinal vein obstruction (RVO), uveitis, diabetic macular edema (DME) and age-related macular degeneration (wAMD and nAMD), etc., avoids repeated administration, reduces the formation of side effects, reduces the cost of drug use, and meets the high stability required by drug preparation in production, storage and transportation, has good application prospect, and meets the unmet clinical needs.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

The invention relates to an application of prunella vulgaris phenolic acid in preparation of a product for preventing, treating and / or relieving liver injury complicated with uveitis. Researches show that prunella vulgaris phenolic acid improves the symptoms such as vasodilatation, iris congestion and pupil tightening, obviously reduces the eye score, can effectively improve D-GalN / LPS induced retinopathy, effectively reduces the content of ALT and AST in serum and improves D-GalN / LPS induced liver injury, and it is indicated that prunella vulgaris phenolic acid can relieve and treat liver injury combined uveitis. The application provides a new application for prunella vulgaris phenolic acid, and provides a new product for preventing, treating and / or relieving D-GalN / LPS induced liver injury combined uveitis at the same time.

Some embodiments of the invention advantageously leverage the expansion, dilation or by-pass of the Schlemm's canal using adjustable reversible self-expanding eye stents (SES) or eye tension rings (ETRs) of desired sizes to control and improve aqueous flow throughout the range of the uveolymphatic canal. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the Schlemm's canal wall and is at least partially within the canal and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the wall and / or elsewhere in the canal. The partial or complete expansion of the canal can be pre-configured based on pre-operative metrology of the Schlemm's canal to a customized and adjustable fit across the various zones within the uveolymphatic canal and based on the patient specific and evolving needs. Additionally, the SES can utilize entry / exit features for by-pass of fluid, varying control of dilation across its shape that may also allow anchoring, repositioning, and retrieval.

The invention relates to an application of an rAAV-mediated PEDF gene in treatment of uveitis, specifically, a recombinant adeno-associated virus is used as a gene delivery carrier, the PEDF gene is efficiently introduced into a vitreous cavity, and continuous and stable expression of PEDF in eyes is realized, so that the PEDF is used for treating autoimmune uveitis, and a new thought is provided for development and treatment of new clinical drugs for uveitis.

Methods for sensitive and reliable qualitative detection and identification of the common pathogens associated with ocular infections, including uveitis, endophthalmitis and keratitis.

The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) “back of the eye” retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2. The disclosed compounds exhibit enhanced aqueous solubility and formulation, as well as elimination of non-binding isomers during production. The disclosed inhibitor compounds can be used to effectively treat ophthalmic diseases, cancers, appetite disorders, systemic inflammatory diseases, and the like.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a novel glucocorticoid and a preparation method and application thereof, the novel glucocorticoid comprises a compound of a formula I, an optical isomer of the compound, a medicinal salt of the compound or a solvate of the compound, and the structural formula of the compound of the formula I is shown in the description. The compound provided by the invention has the advantages of high plasma removal rate, short half-life period, low systemic drug exposure and higher target selectivity to a glucocorticoid receptor (GR), and can obviously reduce side effects caused by systemic absorption of a glucocorticoid drug. The compound has remarkable anti-inflammatory activity on animal asthma, uveitis, xerophthalmia, inflammatory bowel disease, psoriasis and the like. The compound provided by the invention has good safety, no abnormal intraocular pressure is detected when the compound is continuously administered to the eyes of guinea pigs, and no obvious abnormal epidermal layer thickness occurs after the compound is continuously administered to the skin of rats.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

The present invention relates to a method for predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The present invention also relates to an IL-6 antagonist for use in treating uveitis or uveitic macular edema.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

To provide a sustained release microemulsion for reducing intraocular pressure (IOP), treating glaucoma, treating age-related macular degeneration (AMD), treating uveitis, and / or treating conjunctivitis; and to provide a method for treating eye diseases comprising administering the microemulsion.SOLUTION: Provided is a microemulsion (ME) containing: (a) a discontinuous internal phase containing an aqueous solution contained within an internal emulsifier; (b) a continuous oil phase containing the internal phase; and (c) an external emulsifier containing the oil phase. Also provided are a method for the use of such a microemulsion as a drug delivery device, as well as a method for treating glaucoma and reducing intraocular pressure.SELECTED DRAWING: None

The present disclosure relates to peptide compositions and methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. The peptide compositions disclosed herein can also be used for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, pain resulting from nerve injury or nerve degeneration, and pain resulting from an inflammatory condition, dysesthesia, or allodynia.

The invention relates to an ophthalmic implant (20) for permanent insertion between sclera and uveal tissue, comprising a uveal compatible implant body (22) extending along a main axis (A) intended to be oriented in an anterior-posterior direction, the implant body comprises an upper surface (32) intended to face the sclera and a lower surface (34) intended to come into contact with the uveal tissue, the implant body further comprising a first edge (24), referred to as the anterior edge, intended to be oriented towards the anterior chamber of the eye and a second edge (26), referred to as the posterior edge, opposite the anterior edge relative to the implant body. The lower surface is smooth, and the implant body includes one or more protrusions (36) extending from the upper surface toward the exterior of the body to allow the one or more protrusions to contact the sclera and to separate the sclera from the upper surface of the implant body.